WeForNews | Latest News, Breaking News, News Updates Govt sets Rs 2.1 lakh cr disinvestment target for FY21 | WeForNews | Latest News, Blogs
Connect with us

Blog

Govt sets Rs 2.1 lakh cr disinvestment target for FY21

“Listing on the stock exchanges disciplines the company, provides access to financial markets and unlocks value. It also gives an opportunity to retail investors to take part in the wealth so created,”

Published

on

Centre proposes Disinvestment

New Delhi, Feb 1 : The government has set a divestment target of Rs 2.1 lakh crore for FY21 on the back of planned listing of LIC and privatisation of Air India and BPCL, and it’s around Rs 1 lakh crore more than the FY20 goal of Rs 1.05 lakh crore.

The government has made divestment worth Rs 18,094.59 crore this year, so far.

Finance Minister Nirmala Sitharaman said on Saturday the government would sell a part of its stake in Life Insurance Corporation (LIC) through initial public offering (IPO). It, along with Air India, BPCL and others, is expected to contribute substantially to the FY21 divestment target.

LIC, fully owned by the government, is a big investor in share sales, including IPOs of state-run companies.

The Rs 2.1 lakh crore FY21 target is far above the analyst estimates of Rs 1 lakh crore.

“Listing on the stock exchanges disciplines the company, provides access to financial markets and unlocks value. It also gives an opportunity to retail investors to take part in the wealth so created,” said Sitharaman.

This year’s share sale included two IPOs — Rail Vikas Nigam (Rs 475.89 crore) and IRCTC (Rs 637.97 crore) — an OFS by RITES amounting to Rs 730 crore, CPSE ETF worth Rs 10,000 crore and Bharat 22 ETF at Rs 4,368.80 crore. The government also sold enemy shares worth Rs 1,881.21 crore, as per the Dipam.

“LIC has been used as a sovereign fund to support market sentiments. With it’s disinvestment, such direct involvement of the government in the market, will get truncated”, said Vishwas Panjiar, Partner Nangia Andersen.

Blog

Male sex hormones may help treat breast cancer: Study

While endocrine therapy is standard-of-care for estrogen receptor positive breast cancer, resistance to these drugs is the major cause of breast cancer mortality.

Published

on

By

breast cancer

Sydney : Researchers have found new evidence about the positive role of androgens, commonly thought of as male sex hormones but also found at lower levels in women, in breast cancer treatment.

In normal breast development, estrogen stimulates and androgen inhibits growth at puberty and throughout adult life.

Abnormal estrogen activity is responsible for the majority of breast cancers, but the role of androgen activity in this disease has been controversial.

The new research published in the journal Nature Medicine showed that androgens have potential for treatment of estrogen receptor positive breast cancer.

A cancer is called estrogen receptor positive if it has receptors for estrogen, according to Breastcancer.org.

Using cell-line and patient-derived models, the global team, including researchers at the University of Adelaide and the Garvan Institute of Medical Research in Australia, demonstrated that androgen receptor activation by natural androgen or a new androgenic drug had potent anti-tumour activity in all estrogen receptor positive breast cancers, even those resistant to current standard-of-care treatments.

In contrast, androgen receptor inhibitors had no effect.

“This work has immediate implications for women with metastatic estrogen receptor positive breast cancer, including those resistant to current forms of endocrine therapy,” said lead researcher Theresa Hickey, Associate Professor at the University of Adelaide.

“We provide compelling new experimental evidence that androgen receptor stimulating drugs can be more effective than existing (e.g. Tamoxifen) or new (e.g. Palbociclib) standard-of-care treatments and, in the case of the latter, can be combined to enhance growth inhibition,” said Wayne Tilley, Director of the Dame Roma Mitchell Cancer Research Laboratories, Adelaide Medical School, University of Adelaide.

Androgens were historically used to treat breast cancer, but knowledge of hormone receptors in breast tissue was rudimentary at the time and the treatment’s efficacy misunderstood.

Androgen therapy was discontinued due to virilising side effects and the advent of anti-estrogenic endocrine therapies.

While endocrine therapy is standard-of-care for estrogen receptor positive breast cancer, resistance to these drugs is the major cause of breast cancer mortality.

“The new insights from this study should clarify the widespread confusion over the role of the androgen receptor in estrogen receptor driven breast cancer,” said Elgene Lim, a breast oncologist and Head of the Connie Johnson Breast Cancer Research Lab at the Garvan Institute.

“Given the efficacy of this treatment strategy at multiple stages of disease in our study, we hope to translate these findings into clinical trials as a new class of endocrine therapy for breast cancer.”

Continue Reading

Blog

Azim Premji and Dr Devi Shetty chosen for PCB awards

Besides them 25 senior journalists have been selected for the ‘Press Club Annual Awards’, a release said.

Published

on

By

Azim Premji Wipro

Bengaluru, Jan 19: The chairman of Wipro Limited Azim Premji and the founder chairman of Narayana Health Dr Devi Prasad Shetty are among those who have been selected for the annual awards given by the Press Club of Bangalore.

Premji has been chosen for ‘Press Club Person of the Year’, while Dr Shetty and actor-Director Sudeep Sanjeev have been selected for the ‘Press Club Special Award.’

Besides them 25 senior journalists have been selected for the ‘Press Club Annual Awards’, a release said.

Chief Minister B S Yediyurappa will facilitate the awardees at a function scheduled for the third week of February, it said.

Continue Reading

Blog

Elizabeth Olsen: Nepotism creates fear that you don’t deserve the work you get

The actress added that she “always had this need to prove myself to everyone around me that I work really hard”, adding: “I couldn’t walk in a room without everyone already having an opinion.”

Published

on

By

Elizabeth Olsen

Los Angeles, Jan 19 : Hollywood star Elizabeth Olsen says she once thought of changing her surname and distance herself from the success of her family because it was insanity growing up in the spotlight.

“It was insanity. There were times when my sisters would always be spotted and I would be in the car with them and it would really freak me out. It has helped me navigate how I want to approach my career,” said the actress, whose older sisters are Mary-Kate Olsen and Ashley Olsen.

The actress added that she “always had this need to prove myself to everyone around me that I work really hard”, adding: “I couldn’t walk in a room without everyone already having an opinion.”

Elizabeth opened up om the fears of nepotism.

“The thing about nepotism is the fear that you don’t earn or deserve the work. There was even a part of me when I was a little girl that thought if I’m gonna be an actress I’m going to go by Elizabeth Chase, which is my middle name. And then, once I started working, I was like, ‘I love my family, I like my name, I love my sisters. Why would I be so ashamed of that?’ It’s fine now,” she said.

The actress said fame has made her more of a homebody.

“Fame has also made me someone who is more of a homebody than maybe I would like to be but I know where not to go. If I could do whatever I wanted for the day, I’d start with the gym, then I’d go to the grocery store, because it’s my favourite thing,” Elizabeth told The Sun.

Continue Reading
Advertisement

Most Popular